Jun Wang1,2, Sabina Krizowski3, Katrin Fischer-Schrader3, Dimitri Niks4, Jesús Tejero1,2, Courtney Sparacino-Watkins1,2, Ling Wang1,2, Venkata Ragireddy1,2, Sheila Frizzell1,2, Eric E Kelley1,5, Yingze Zhang2, Partha Basu6, Russ Hille4, Guenter Schwarz3, Mark T Gladwin1,2. 1. 1 Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh , Pittsburgh, Pennsylvania. 2. 2 Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania. 3. 3 Department of Biochemistry, Center for Molecular Medicine, Institute of Biochemistry, Cologne University , Cologne, Germany . 4. 4 Department of Biochemistry, University of California at Riverside , Riverside, California. 5. 5 Department of Anesthesiology, University of Pittsburgh , Pittsburgh, Pennsylvania. 6. 6 Department of Chemistry and Biochemistry, Duquesne University , Pittsburgh, Pennsylvania.
Abstract
AIMS: Recent studies suggest that the molybdenum enzymes xanthine oxidase, aldehyde oxidase, and mARC exhibit nitrite reductase activity at low oxygen pressures. However, inhibition studies of xanthine oxidase in humans have failed to block nitrite-dependent changes in blood flow, leading to continued exploration for other candidate nitrite reductases. Another physiologically important molybdenum enzyme—sulfite oxidase (SO)—has not been extensively studied. RESULTS: Using gas-phase nitric oxide (NO) detection and physiological concentrations of nitrite, SO functions as nitrite reductase in the presence of a one-electron donor, exhibiting redox coupling of substrate oxidation and nitrite reduction to form NO. With sulfite, the physiological substrate, SO only facilitates one turnover of nitrite reduction. Studies with recombinant heme and molybdenum domains of SO indicate that nitrite reduction occurs at the molybdenum center via coupled oxidation of Mo(IV) to Mo(V). Reaction rates of nitrite to NO decreased in the presence of a functional heme domain, mediated by steric and redox effects of this domain. Using knockdown of all molybdopterin enzymes and SO in fibroblasts isolated from patients with genetic deficiencies of molybdenum cofactor and SO, respectively, SO was found to significantly contribute to hypoxic nitrite signaling as demonstrated by activation of the canonical NO-sGC-cGMP pathway. INNOVATION: Nitrite binds to and is reduced at the molybdenum site of mammalian SO, which may be allosterically regulated by heme and molybdenum domain interactions, and contributes to the mammalian nitrate-nitrite-NO signaling pathway in human fibroblasts. CONCLUSION: SO is a putative mammalian nitrite reductase, catalyzing nitrite reduction at the Mo(IV) center.
AIMS: Recent studies suggest that the molybdenum enzymes xanthine oxidase, aldehyde oxidase, and mARC exhibit nitrite reductase activity at low oxygen pressures. However, inhibition studies of xanthine oxidase in humans have failed to block nitrite-dependent changes in blood flow, leading to continued exploration for other candidate nitrite reductases. Another physiologically important molybdenum enzyme—sulfite oxidase (SO)—has not been extensively studied. RESULTS: Using gas-phase nitric oxide (NO) detection and physiological concentrations of nitrite, SO functions as nitrite reductase in the presence of a one-electron donor, exhibiting redox coupling of substrate oxidation and nitrite reduction to form NO. With sulfite, the physiological substrate, SO only facilitates one turnover of nitrite reduction. Studies with recombinant heme and molybdenum domains of SO indicate that nitrite reduction occurs at the molybdenum center via coupled oxidation of Mo(IV) to Mo(V). Reaction rates of nitrite to NO decreased in the presence of a functional heme domain, mediated by steric and redox effects of this domain. Using knockdown of all molybdopterin enzymes and SO in fibroblasts isolated from patients with genetic deficiencies of molybdenum cofactor and SO, respectively, SO was found to significantly contribute to hypoxic nitrite signaling as demonstrated by activation of the canonical NO-sGC-cGMP pathway. INNOVATION: Nitrite binds to and is reduced at the molybdenum site of mammalian SO, which may be allosterically regulated by heme and molybdenum domain interactions, and contributes to the mammaliannitrate-nitrite-NO signaling pathway in human fibroblasts. CONCLUSION: SO is a putative mammaliannitrite reductase, catalyzing nitrite reduction at the Mo(IV) center.
Authors: M T Gladwin; J H Shelhamer; A N Schechter; M E Pease-Fye; M A Waclawiw; J A Panza; F P Ognibene; R O Cannon Journal: Proc Natl Acad Sci U S A Date: 2000-10-10 Impact factor: 11.205
Authors: Andrew Webb; Richard Bond; Peter McLean; Rakesh Uppal; Nigel Benjamin; Amrita Ahluwalia Journal: Proc Natl Acad Sci U S A Date: 2004-09-03 Impact factor: 11.205
Authors: HåKan Björne H; Joel Petersson; Mia Phillipson; Eddie Weitzberg; Lena Holm; Jon O Lundberg Journal: J Clin Invest Date: 2004-01 Impact factor: 14.808
Authors: Martin Feelisch; Bernadette O Fernandez; Nathan S Bryan; Maria Francisca Garcia-Saura; Selena Bauer; David R Whitlock; Peter C Ford; David R Janero; Juan Rodriguez; Houman Ashrafian Journal: J Biol Chem Date: 2008-10-03 Impact factor: 5.157
Authors: Yuen Yi Hon; Elaina E Lin; Xin Tian; Yang Yang; He Sun; Erik R Swenson; Angelo M Taveira-Dasilva; Mark T Gladwin; Roberto F Machado Journal: Am J Physiol Lung Cell Mol Physiol Date: 2015-12-18 Impact factor: 5.464
Authors: Courtney E Sparacino-Watkins; Jesús Tejero; Bin Sun; Marc C Gauthier; John Thomas; Venkata Ragireddy; Bonnie A Merchant; Jun Wang; Ivan Azarov; Partha Basu; Mark T Gladwin Journal: J Biol Chem Date: 2014-02-05 Impact factor: 5.157
Authors: H Diessel Duan; Carolyn E Lubner; Monika Tokmina-Lukaszewska; George H Gauss; Brian Bothner; Paul W King; John W Peters; Anne-Frances Miller Journal: J Biol Chem Date: 2018-02-09 Impact factor: 5.157
Authors: Kara S Hughan; Andrea Levine; Nicole Helbling; Steven Anthony; James P DeLany; Maja Stefanovic-Racic; Bret H Goodpaster; Mark T Gladwin Journal: Hypertension Date: 2020-08-03 Impact factor: 10.190
Authors: Ling Wang; Courtney E Sparacino-Watkins; Jun Wang; Nadeem Wajih; Paul Varano; Qinzi Xu; Eric Cecco; Jesús Tejero; Manoocher Soleimani; Daniel B Kim-Shapiro; Mark T Gladwin Journal: Br J Pharmacol Date: 2019-12-23 Impact factor: 8.739